FDA approved Moderna’s seasonal flu vaccine for adults aged 50 and older, marking the first messenger RNA (mRNA) flu vaccine approval. The action is a positive product milestone for Moderna and supports near- to medium-term commercial upside as the company expands its vaccine franchise.
FDA approved Moderna’s seasonal flu vaccine for adults aged 50 and older, marking the first messenger RNA (mRNA) flu vaccine approval. The action is a positive product milestone for Moderna and supports near- to medium-term commercial upside as the company expands its vaccine franchise.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
